Related Experiment Videos
The anticholinergic biperiden in depressive disorders
Pharmacopsychiatria
|November 1, 1981
Summary
Biperiden, an anticholinergic drug, significantly improved depression symptoms in severely depressed patients. However, some experienced adverse effects, suggesting a complex role for cholinergic mechanisms in depression.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Cholinergic systems are implicated in mood regulation.
- Anticholinergic medications have been explored for depression treatment.
- Understanding the role of cholinergic pathways in depression is crucial for developing effective therapies.
Purpose of the Study:
- To evaluate the efficacy and safety of biperiden in treating severe depression.
- To explore the relationship between baseline cortisol non-suppressability and treatment response.
Main Methods:
- An open-label study involving 10 severely depressed inpatients.
- Biperiden administered at an average dose of 12 mg/day for 30 days.
- Patients assessed using the Hamilton Depression Scale and classified by diagnostic criteria.
Main Results:
- Significant global improvement in Hamilton Depression Scale scores (p < 0.001).
- Notable improvements in retardation, agitation, depressed mood, insomnia, work/interest, and gastrointestinal symptoms.
- Two patients discontinued treatment due to adverse effects (paranoid syndrome, inner restlessness).
- Positive correlation between clinical response and cortisol non-suppressability (p < 0.03).
Conclusions:
- Biperiden demonstrates efficacy in alleviating severe depression symptoms.
- Cholinergic mechanisms appear to play a significant role in the pathogenesis of certain depression subtypes.
- Further research is warranted to elucidate the precise role of cholinergic pathways and optimize anticholinergic treatment strategies.